IRWDIronwood Pharmaceuticals, Inc. - Class A

CSNasdaq (XNAS)·USD

Identity

Security key: 17245
Ticker: IRWD
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2010-02-03
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: IRWD

Detail

Enriched 2026-08-14 20:47

Market cap: $713,836,571.04
Shares outstanding (class): 164,613,406
Shares outstanding (weighted): 165,239,947
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 100
Location: BOSTON, MA
Homepage: https://www.ironwoodpharma.com
Description: Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Market cap and share counts drift.

Funds holding this security

119 funds · 119 positions · $96.64M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$15.22M	0.00%	4,334,784 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$14.04M	0.19%	3,999,224 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$13.89M	0.02%	3,957,233 NS	FIGI
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$7.38M	0.07%	2,102,573 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$5.66M	0.01%	1,612,143 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$4.25M	0.03%	1,209,938 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$4.12M	0.05%	1,173,471 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$3.16M	0.03%	901,494 NS	FIGI
VictoryShares Small Cap Free Cash Flow ETF Victory Portfolios II	SFLO	$2.44M	0.49%	695,161 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$2.18M	0.05%	621,720 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$1.41M	0.12%	402,901 NS	FIGI
VANGUARD MARKET NEUTRAL FUND VANGUARD MONTGOMERY FUNDS	—	$1.11M	0.26%	315,160 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$1.05M	0.04%	300,277 NS	FIGI
Amplify Etho Climate Leadership U.S. ETF Amplify ETF Trust	—	$1.02M	0.66%	290,771 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$955.4K	0.02%	272,189 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERIRWD
FIGI_COMPOSITEBBG000GBZ3J2
FIGI_SHARE_CLASSBBG001SNZLM7
CIK0001446847
ISINUS46333X1081
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Ironwood Pharmaceuticals is a biopharmaceutical company focused on gastrointestinal products, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.